Bleb Vascularity Change After Subconjunctival Injection Bevacizumab
- Sponsor
- Capital Medical University
- Study ID
- NCT00815594
- Phase
- PHASE4
- Status
- Unknown
Conditions
- Bleb Vascularity
- Conjunctival Scarring
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- bevacizumab — DRUG0.05ml, 1.25mg
Study Details
The occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery. Vascular endothelial growth factor is thought to be a key role in the formation of conjunctival scar, which play a pivotal role in the wound-healing process. So it seems that the recombinant human anti-VEGF antibody could inhibit angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process after glaucoma filtering surgery.
Key Dates
- First listed
- Dec 30, 2008
- Start date
- Dec 31, 2008
- Status verified
- Dec 2008
- Primary completion
- Mar 31, 2009
- Completion
- May 31, 2009
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
bleb vascular change [ Time Frame: one day, one week, one month ]